Diabetes, Vol 42, Issue 2 330-335, Copyright © 1993 by American Diabetes Association

ARTICLES

Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets

ZL Wang, WM Bennet, MA Ghatei, PG Byfield, DM Smith and SR Bloom
Department of Medicine, Royal Postgraduate Medical School, London, U.K.

IAPP, or amylin, is a 37-amino acid peptide that is co-secreted with insulin from the pancreatic beta-cells. We have determined the effects of IAPP and the antagonist 8-37 fragment of IAPP on the secretion of insulin from isolated rat islets studied in a perifusion system. Insulin secretion was stimulated by 8 mM glucose and 0.2 microM carbachol. IAPP at 10(-7) M reduced insulin release by 32% from 7.1 (95% Cl 5.8-8.6) to 4.8 (3.0-7.5) fmol.min-1 x islet-1 (P = 0.046, n = 7). IAPP at 1.5 x 10(-6) M reduced insulin release by 62% from 6.5 (3.4-12.3) to 2.5 (1.4-4.4) fmol.min-1 x islet-1 (P = 0.001, n = 6). IAPP at 10(-5) M decreased insulin release by 70% (P < 0.001, n = 6). When IAPP (8-37) at 10(-5) M was added to IAPP at 1.5 x 10(-6) M, there was only a 22% reduction of insulin release (P = 0.06, n = 6) compared with control chambers with no peptide added. This reduction was less (P = 0.002) than observed with IAPP (1.5 x 10(-6) M) alone. IAPP (8-37) at 4 x 10(-5) M in the absence of exogenously added IAPP increased insulin secretion by 48% (P = 0.01, n = 6), but IAPP (8-37) at 10(-5) M did not alter insulin secretion. These findings demonstrate that IAPP decreases insulin secretion from islet beta-cells, an effect that can be antagonized by the 8-37 fragment of IAPP.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. L. Hay, G. Christopoulos, A. Christopoulos, D. R. Poyner, and P. M. Sexton Pharmacological Discrimination of Calcitonin Receptor: Receptor Activity-Modifying Protein Complexes Mol. Pharmacol., May 1, 2005; 67(5): 1655 - 1665. [Abstract] [Full Text] [PDF]

				O. Schmitz, B. Brock, and J. Rungby Amylin Agonists: A Novel Approach in the Treatment of Diabetes Diabetes, December 1, 2004; 53(suppl_3): S233 - S238. [Abstract] [Full Text] [PDF]

				J.-M. Ye, M. Lim-Fraser, G. J. Cooney, G. J. S. Cooper, M. A. Iglesias, D. G. Watson, B. Choong, and E. W. Kraegen Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance Am J Physiol Endocrinol Metab, April 1, 2001; 280(4): E562 - E569. [Abstract] [Full Text] [PDF]

				R. A. Silvestre, J. Rodriguez-Gallardo, C. Jodka, D. G. Parkes, R. A. Pittner, A. A. Young, and J. Marco Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas Am J Physiol Endocrinol Metab, March 1, 2001; 280(3): E443 - E449. [Abstract] [Full Text] [PDF]

				F. Wang, T. E. Adrian, G. T. Westermark, X. Ding, T. Gasslander, and J. Permert Islet amyloid polypeptide tonally inhibits beta -, alpha -, and delta -cell secretion in isolated rat pancreatic islets Am J Physiol Endocrinol Metab, January 1, 1999; 276(1): E19 - E24. [Abstract] [Full Text] [PDF]

				M. Hettiarachchi, S. Chalkley, S. M. Furler, Y.-S. Choong, M. Heller, G. J. S. Cooper, and E. W. Kraegen Rat amylin-(8---37) enhances insulin action and alters lipid metabolism in normal and insulin-resistant rats Am J Physiol Endocrinol Metab, November 1, 1997; 273(5): E859 - E867. [Abstract] [Full Text] [PDF]